HC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Spero Therapeutics (NASDAQ:SPRO) and increased its price target from $6.00 to $7.00. This new target represents a 412.82% increase from the current share price. Spero Therapeutics, a clinical-stage biopharmaceutical firm, is currently trading down 2.5% at $1.36 per share.
August 14, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spero Therapeutics' stock could potentially see a significant increase in the short term due to the raised price target by HC Wainwright & Co.
The raised price target by HC Wainwright & Co. indicates a strong positive outlook for Spero Therapeutics. This could potentially attract more investors, driving up the demand and price of the stock in the short term.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100